Int J Gynecol Cancer
-
Publication Venue For
- Role of stereotactic body radiotherapy in gynecologic radiation oncology.. 32:372-379. 2022
- Adjuvant treatment and outcomes for patients with stage IIIA grade 1 endometrioid endometrial cancer.. 31:1549-1556. 2021
- Adjuvant brachytherapy for FIGO stage I serous or clear cell endometrial cancer.. 31:859-867. 2021
- Development of a surgical competency assessment tool for sentinel lymph node dissection by minimally invasive surgery for endometrial cancer.. 31:647-655. 2021
- Facilitated cascade testing (FaCT): a randomized controlled trial.. 31:779-783. 2021
- Pathologic distribution at the time of interval tumor reductive surgery informs personalized surgery for high-grade ovarian cancer.. 31:232-237. 2021
- The right question in the right database: epidural analgesia for gynecological oncologic surgery.. 30:2019. 2020
- Adjuvant treatment improves overall survival in women with high-intermediate risk early-stage endometrial cancer with lymphovascular space invasion.. 30:1738-1747. 2020
- Management of high, moderate, and low penetrance ovarian cancer susceptibility mutations: an assessment of current risk reduction practices.. 30:1583-1588. 2020
- Incidence of venous thromboembolism among patients receiving neoadjuvant chemotherapy for advanced epithelial ovarian cancer.. 30:491-497. 2020
- Defining the learning curve for successful staging with sentinel lymph node biopsy for endometrial cancer among surgeons at an academic institution.. 30:346-351. 2020
- Association of human papilloma virus status and response to radiotherapy in vulvar squamous cell carcinoma.. 30:100-106. 2020
- Reduction in opioid use and postoperative pain scores after elective laparotomy with implementation of enhanced recovery after surgery protocol on a gynecologic oncology service.. 29:935-943. 2019
- Current state of sentinel lymph nodes for women with endometrial cancer.. 29:613-621. 2019
- Predicting 6- and 12-Month Risk of Mortality in Patients With Platinum-Resistant Advanced-Stage Ovarian Cancer: Prognostic Model to Guide Palliative Care Referrals.. 28:302-307. 2018
- Low-Volume Lymph Node Metastases in Endometrial Carcinoma.. 27:1165-1170. 2017
- Impact of Chemotherapy and Radiotherapy on Management of Early Stage Clear Cell and Papillary Serous Carcinoma of the Uterus.. 27:720-729. 2017
- Placenta-Specific Protein 1 Expression in Human Papillomavirus 16/18-Positive Cervical Cancers Is Associated With Tumor Histology.. 27:784-790. 2017
- Primary Versus Preoperative Radiation for Locally Advanced Vulvar Cancer.. 27:794-804. 2017
- Definitive Chemoradiotherapy for Vulvar Cancer.. 26:1699-1705. 2016
- Does Routine Posttreatment PET/CT Add Value to the Care of Women With Locally Advanced Cervical Cancer?. 26:944-950. 2016
- LIFETIME RISK OF OVARIAN CANCER BASED ON ENDOMETRIOSIS AND OTHER RISK FACTORS: IGCS-0014 06. Ovarian Cancer.. 25 Suppl 1:50. 2015
- Obesity is associated with worse overall survival in women with low-grade papillary serous epithelial ovarian cancer.. 24:670-675. 2014
- Risk factors for ovarian cancers with and without microsatellite instability.. 24:664-669. 2014
- Dasatinib (BMS-35482) interacts synergistically with docetaxel, gemcitabine, topotecan, and doxorubicin in ovarian cancer cells with high SRC pathway activation and protein expression.. 24:218-225. 2014
- Detection of sentinel nodes for endometrial cancer with robotic assisted fluorescence imaging: cervical versus hysteroscopic injection.. 23:1704-1711. 2013
- Preference-based utility scores for adverse events associated with the treatment of gynecologic cancers.. 23:1158-1166. 2013
- Risk factors for ovarian cancers with and without microsatellite instability.. 23:1010-1015. 2013
- Cost-effectiveness of BRCA1 and BRCA2 mutation testing to target PARP inhibitor use in platinum-sensitive recurrent ovarian cancer.. 23:846-852. 2013
- Antiangiogenic agents in combination with chemotherapy for the treatment of epithelial ovarian cancer.. 22:348-359. 2012
- Loss of ARID1A-associated protein expression is a frequent event in clear cell and endometrioid ovarian cancers.. 22:9-14. 2012
- Religious and spiritual beliefs of gynecologic oncologists may influence medical decision making.. 21:573-581. 2011
- Attitudes regarding the use of hematopoietic colony-stimulating factors and maintenance of relative dose intensity among gynecologic oncologists.. 19:447-454. 2009
- A multi-institutional evaluation of factors predictive of toxicity and efficacy of bevacizumab for recurrent ovarian cancer.. 18:400-406. 2008
- Desmoplastic small round cell tumor masquerading as advanced ovarian cancer.. 18:847-850. 2008
- Co-expression of p53 by epithelial and stromal elements in carcinosarcoma of the female genital tract: an immunohistochemical study of 19 cases.. 9:131-136. 1999